Patient-reported outcomes among people living with HIV switching to dual therapy with dolutegravir/lamivudine: results from the PROBI study.

ABSTRACT:

Background

Simplification of antiretroviral regimens has the potential to improve both patient-reported outcomes (PROs) and therapeutic adherence in people living with HIV (PLWH). Dual therapy with dolutegravir (DTG) plus lamivudine (3TC) demonstrated good safety and efficacy, but its impact on PROs remains to be documented.

Objectives

To evaluate PROs among adult PLWH switching from standard multi-drug therapy to the DTG/3TC combined therapy Dovato^®.

Design

A non-comparative, 6-month observational study in 25 French medical centers.

Methods

Sociodemographic and biomedical data were collected from medical records and PROs from self-administered questionnaires at treatment switch (Day, D0) and at months (M) 1 and 6. Primary endpoints included changes

SUBMITTER: Duracinsky M 

PROVIDER: S-EPMC12534816 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature